

## DAFTAR PUSTAKA

- Al-Rashed, F., Ahmad, Z., Iskandar, M. A., Tuomilehto, J., Al-Mulla, F., & Ahmad, R. (2019). TNF- $\alpha$  Induces a Pro-Inflammatory Phenotypic Shift in Monocytes through ACSL1: Relevance to Metabolic Inflammation. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*, 52(3), 397–407. <https://doi.org/10.33594/000000028>
- Amr, K. S., Elmawgoud Atia, H. A., Elazeem Elbnhawy, R. A., & Ezzat, W. M. (2017). Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma. *Genes & diseases*, 4(4), 215–221. <https://doi.org/10.1016/j.gendis.2017.10.003>
- Arrieta, O., Cacho, B., Morales-Espinosa, D., Ruelas-Villavicencio, A., Flores-Estrada, D., & Hernández-Pedro, N. (2007). The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. *BMC cancer*, 7, 28. <https://doi.org/10.1186/1471-2407-7-28>
- Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019). Burden of liver diseases in the world. *Journal of hepatology*, 70(1), 151–171. <https://doi.org/10.1016/j.jhep.2018.09.014>
- Axley, P., Ahmed, Z., Ravi, S., & Singal, A. K. (2018). Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. *Journal of clinical and translational hepatology*, 6(1), 79–84. <https://doi.org/10.14218/JCTH.2017.00067>
- Balogh, J., Victor, D., 3rd, Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., Li, X., Ghobrial, R. M., & Monsour, H. P., Jr (2016). Hepatocellular carcinoma: a review. *Journal of hepatocellular carcinoma*, 3, 41–53. <https://doi.org/10.2147/JHC.S61146>
- Bandiera, S., Pfeffer, S., Baumert, T. F., & Zeisel, M. B. (2015). miR-122--a key factor and therapeutic target in liver disease. *Journal of hepatology*, 62(2), 448–457. <https://doi.org/10.1016/j.jhep.2014.10.004>
- Barghini, V., Donnini, D., Uzzau, A., & Giorgio Soardo, G. (2013). Signs and Symptoms. In (Ed.). *Hepatocellular Carcinoma - Future Outlook*. IntechOpen. <https://doi.org/10.5772/56162>
- Boozarpour, S., Mashregi, M., Mirahmadi, M. (2014). Mechanisms of hepatitis B virus-induced hepatocellular carcinoma. *Reviews in Medical Microbiology*, 25(1), 20–25. doi: 10.1097/MRM.0b013e328365c4c3
- Bosetti, C., Turati, F., & La Vecchia, C. (2014). Hepatocellular carcinoma epidemiology. Best practice & research. *Clinical gastroenterology*, 28(5), 753–770. <https://doi.org/10.1016/j.bpg.2014.08.007>
- Cai, P., Mu, Y., Olveda, R. M., Ross, A. G., Olveda, D. U., & McManus, D. P. (2018). Circulating miRNAs as footprints for liver fibrosis grading in schistosomiasis. *EBioMedicine*, 37, 334–343. <https://doi.org/10.1016/j.ebiom.2018.10.048>

- Cassinotto, C., Aubé, C., & Dohan, A. (2017). Diagnosis of hepatocellular carcinoma: An update on international guidelines. *Diagnostic and interventional imaging*, 98(5), 379–391. <https://doi.org/10.1016/j.diii.2017.01.014>
- Chang, W. A., Tsai, M. J., Hung, J. Y., Wu, K. L., Tsai, Y. M., Huang, Y. C., Chang, C. Y., Tsai, P. H., & Hsu, Y. L. (2021). miR-150-5p-Containing Extracellular Vesicles Are a New Immunoregulator That Favor the Progression of Lung Cancer in Hypoxic Microenvironments by Altering the Phenotype of NK Cells. *Cancers*, 13(24), 6252. <https://doi.org/10.3390/cancers13246252>
- Chen, W., Fan, X. M., Mao, L., Zhang, J. Y., Li, J., Wu, J.Z., Tang, J. H. (2015). MicroRNA-224: as a potential target for miR-based therapy of cancer. *Tumor Biology*, 36, 6645–6652. <https://doi.org/10.1007/s13277-015-3883-3>
- Chen, W., Yan, X., Yang, A., Xu, A., Huang, T., & You, H. (2020). miRNA-150-5p promotes hepatic stellate cell proliferation and sensitizes hepatocyte apoptosis during liver fibrosis. *Epigenomics*, 12(1), 53–67. <https://doi.org/10.2217/epi-2019-0104>
- Chen, Y., & Verfaillie, C. M. (2014). MicroRNAs: the fine modulators of liver development and function. *Liver international : official journal of the International Association for the Study of the Liver*, 34(7), 976–990. <https://doi.org/10.1111/liv.12496>
- Cui, M., Wang, Y., Sun, B., Xiao, Z., Ye, L., & Zhang, X. (2014). MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. *Biochemical and biophysical research communications*, 444(2), 270–275. <https://doi.org/10.1016/j.bbrc.2014.01.051>
- Cui, M., Xiao, Z., Wang, Y., Zheng, M., Song, T., Cai, X., Sun, B., Ye, L., & Zhang, X. (2015). Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. *Cancer research*, 75(5), 846–857. <https://doi.org/10.1158/0008-5472.CAN-14-1192>
- Dabbish, A. M., Abdelzaher, H. M., Abohawya, M., Shamma, S., Mahmoud, Y. H., Maged, A., Manaa, M., Hassany, M., Kobeissy, F., Bazgir, O., El-Fawal, H., Azzazy, H., & Abdelnaser, A. (2022). Prognostic MicroRNA Panel for HCV-Associated HCC: Integrating Computational Biology and Clinical Validation. *Cancers*, 14(13), 3036. <https://doi.org/10.3390/cancers14133036>
- Dahlan, M.S., 2016. *Besar Sampel dalam Penelitian Kedokteran dan Kesehatan* (4th ed). Epidemiologi Indonesia.
- D'Amico, G., Bernardi, M., & Angeli, P. (2022). Towards a new definition of decompensated cirrhosis. *Journal of hepatology*, 76(1), 202–207. <https://doi.org/10.1016/j.jhep.2021.06.018>
- de Kroon, L. M., Narcisi, R., van den Akker, G. G., Vitters, E. L., Blaney Davidson, E. N., van Osch, G. J., & van der Kraan, P. M. (2017). SMAD3 and SMAD4 have a more dominant role than SMAD2 in TGFβ-induced

- chondrogenic differentiation of bone marrow-derived mesenchymal stem cells. *Scientific reports*, 7, 43164. <https://doi.org/10.1038/srep43164>
- Deng, P., Chen, L., Liu, Z., Ye, P., Wang, S., Wu, J., Yao, Y., Sun, Y., Huang, X., Ren, L., Zhang, A., Wang, K., Wu, C., Yue, Z., Xu, X., & Chen, M. (2016). MicroRNA-150 Inhibits the Activation of Cardiac Fibroblasts by Regulating c-Myb. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*, 38(6), 2103–2122. <https://doi.org/10.1159/000445568>
- Devhare, P. B., Steele, R., Di Bisceglie, A. M., Kaplan, D. E., & Ray, R. B. (2017). Differential Expression of MicroRNAs in Hepatitis C Virus-Mediated Liver Disease Between African Americans and Caucasians: Implications for Racial Health Disparities. *Gene expression*, 17(2), 89–98. <https://doi.org/10.3727/105221616X693594>
- Dhanasekaran, R., Bandoh, S., & Roberts, L. R. (2016). Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. *F1000Research*, 5, F1000 Faculty Rev-879. <https://doi.org/10.12688/f1000research.6946.1>
- Ding, X., Yang, L. Y., Huang, G. W., Wang, W., & Lu, W. Q. (2004). ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. *World journal of gastroenterology*, 10(18), 2735–2739. <https://doi.org/10.3748/wjg.v10.i18.2735>
- Durand, F., & Valla, D. (2005). Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. *Journal of hepatology*, 42 Suppl(1), S100–S107. <https://doi.org/10.1016/j.jhep.2004.11.015>
- Dustin, L. B., Bartolini, B., Capobianchi, M. R., & Pistello, M. (2016). Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*, 22(10), 826–832. <https://doi.org/10.1016/j.cmi.2016.08.025>
- EASL (European Association for the Study of the Liver). Electronic address: [easloffice@easloffice.eu](mailto:easloffice@easloffice.eu), & European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Journal of hepatology*, 69(1), 182–236. <https://doi.org/10.1016/j.jhep.2018.03.019>
- El-Garem, H., Ammer, A., Shehab, H., Shaker, O., Anwer, M., El-Akel, W., & Omar, H. (2014). Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. *World journal of hepatology*, 6(11), 818–824. <https://doi.org/10.4254/wjh.v6.i11.818>
- Ellis, J. M., Bowman, C. E., & Wolfgang, M. J. (2015). Metabolic and tissue-specific regulation of acyl-CoA metabolism. *PloS one*, 10(3), e0116587. <https://doi.org/10.1371/journal.pone.0116587>
- El-Serag, H.B. (2020). Epidemiology of Hepatocellular Carcinoma. In *The liver* (eds I.M. Arias, H.J. Alter, J.L. Boyer, D.E. Cohen, D.A. Shafritz, S.S.

- Thorgeirsson and A.W. Wolkoff). <https://doi.org/10.1002/9781119436812.ch59>
- Fu, Y., & Chung, F. L. (2018). Oxidative stress and hepatocarcinogenesis. *Hepatology research*, 4, 39. <https://doi.org/10.20517/2394-5079.2018.29>
- Galle, P. R., Foerster, F., Kudo, M., Chan, S. L., Llovet, J. M., Qin, S., Schelman, W. R., Chintharlapalli, S., Abada, P. B., Sherman, M., & Zhu, A. X. (2019). Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. *Liver international : official journal of the International Association for the Study of the Liver*, 39(12), 2214–2229. <https://doi.org/10.1111/liv.14223>
- Gani, R.A. (2017). Hepatocellular Carcinoma (HCC) Surveillance – Comprehensive Management in Liver Cirrhosis Patients. *The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy*, 18(3), 137–139. doi:10.24871/1832017137-139
- George, O. L., & Ness, S. A. (2014). Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis. *Cancers*, 6(4), 2049–2071. <https://doi.org/10.3390/cancers6042049>
- Ghouri, Y. A., Mian, I., & Rowe, J. H. (2017). Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. *Journal of carcinogenesis*, 16, 1. [https://doi.org/10.4103/jcar.JCar\\_9\\_16](https://doi.org/10.4103/jcar.JCar_9_16)
- Giray, B. G., Emekdas, G., Tezcan, S., Ulger, M., Serin, M. S., Sezgin, O., Altintas, E., & Tiftik, E. N. (2014). Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. *Molecular biology reports*, 41(7), 4513–4519. <https://doi.org/10.1007/s11033-014-3322-3>
- Goldman, M., Germain, M., Grégoire, Y., Vassallo, R. R., Kamel, H., Bravo, M., Irving, D. O., Di Angelantonio, E., Steele, W. R., O'Brien, S. F., & Biomedical Excellence for Safer Transfusion Collaborative (BEST) Investigators (2019). Safety of blood donation by individuals over age 70 and their contribution to the blood supply in five developed countries: a BEST Collaborative group study. *Transfusion*, 59(4), 1267–1272. <https://doi.org/10.1111/trf.15132>
- Gomes, M. A., Priolli, D. G., Tralhão, J. G., & Botelho, M. F. (2013). Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. *Revista da Associacao Medica Brasileira* (1992), 59(5), 514–524. <https://doi.org/10.1016/j.ramb.2013.03.005>
- Goodman Z. D. (2007). Grading and staging systems for inflammation and fibrosis in chronic liver diseases. *Journal of hepatology*, 47(4), 598–607. <https://doi.org/10.1016/j.jhep.2007.07.006>
- Gooz M. (2010). ADAM-17: the enzyme that does it all. *Critical reviews in biochemistry and molecular biology*, 45(2), 146–169. <https://doi.org/10.3109/10409231003628015>



- Gui, Z. R., Hao, T. Z., Jie, F., Qing, Z. G., Sheng, Y. Y. (2008). The expression of c-myb in HCC tissues and clinical significance. *Journal of Clinical Hepatology*, 24(2), 106–108
- Gumilas, N.S.A., Harini, I.M., Sylviningrum, T., Djatmiko, W., & Rujito, L. (2019). Hepatitis B as hepatocellular carcinoma (HCC) risk factor in the south region of Java, Indonesia. *Journal of Physics: Conference Series* 1246: 012013. <https://doi.org/10.1088/1742-6596/1246/1/012013>
- Guss, D., Sherigar, J., & Mohanty, S. R. (2018). Missed Diagnosis of Liver Cirrhosis Leads to Disparities in Care for Older Patients. *Gastroenterology research*, 11(5), 333–339. <https://doi.org/10.14740/gr1074w>
- H Muljono D. (2017). Epidemiology of Hepatitis B and C in Republic of Indonesia. *Euroasian journal of hepato-gastroenterology*, 7(1), 55–59. <https://doi.org/10.5005/jp-journals-10018-1212>
- Hayes, C. N., & Chayama, K. (2016). MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma. *International journal of molecular sciences*, 17(3), 280. <https://doi.org/10.3390/ijms17030280>
- Hernanda, P. Y., Chen, K., Das, A. M., Sideras, K., Wang, W., Li, J., Cao, W., Bots, S. J., Kodach, L. L., de Man, R. A., Ijzermans, J. N., Janssen, H. L., Stubbs, A. P., Sprengers, D., Bruno, M. J., Metselaar, H. J., ten Hagen, T. L., Kwekkeboom, J., Peppelenbosch, M. P., & Pan, Q. (2015). SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. *Oncogene*, 34(39), 5055–5068. <https://doi.org/10.1038/onc.2014.425>
- Hester, C. A., Rich, N. E., Singal, A. G., & Yopp, A. C. (2019). Comparative Analysis of Nonalcoholic Steatohepatitis- Versus Viral Hepatitis- and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma. *Journal of the National Comprehensive Cancer Network : JNCCN*, 17(4), 322–329. <https://doi.org/10.6004/jnccn.2018.7105>
- Hu, X., Chen, R., Wei, Q., & Xu, X. (2022). The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?. *International journal of biological sciences*, 18(2), 536–551. <https://doi.org/10.7150/ijbs.64537>
- Innes, H., Morling, J. R., Aspinall, E. A., Goldberg, D. J., Hutchinson, S. J., & Guha, I. N. (2020). Late diagnosis of chronic liver disease in a community cohort (UK biobank): determinants and impact on subsequent survival. *Public health*, 187, 165–171. <https://doi.org/10.1016/j.puhe.2020.07.017>
- Irshad, M., Gupta, P., & Irshad, K. (2017). Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection. *World journal of hepatology*, 9(36), 1305–1314. <https://doi.org/10.4254/wjh.v9.i36.1305>
- Jiang, X. P., Ai, W. B., Wan, L. Y., Zhang, Y. Q., & Wu, J. F. (2017). The roles of microRNA families in hepatic fibrosis. *Cell & bioscience*, 7, 34. <https://doi.org/10.1186/s13578-017-0161-7>
- Jin, Y., Wong, Y. S., Goh, B., Chan, C. Y., Cheow, P. C., Chow, P., Lim, T., Goh, G., Krishnamoorthy, T. L., Kumar, R., Ng, T. P., Chong, S. S., Tan, H. H., Chung, A., Ooi, L., Chang, J., Tan, C. K., & Lee, C. (2019).

- Circulating microRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma. *Scientific reports*, 9(1), 10464. <https://doi.org/10.1038/s41598-019-46872-8>
- Jopling C. (2012). Liver-specific microRNA-122: Biogenesis and function. *RNA biology*, 9(2), 137–142. <https://doi.org/10.4161/rna.18827>
- Kamath, P. S., Kim, W. R., & Advanced Liver Disease Study Group (2007). The model for end-stage liver disease (MELD). *Hepatology* (Baltimore, Md.), 45(3), 797–805. <https://doi.org/10.1002/hep.21563>
- Kementerian Kesehatan Republik Indonesia. (2015). *Situasi Penyakit Kanker*. <https://pusdatin.kemkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf>
- Kementerian Kesehatan Republik Indonesia. (2017). *150 ribu orang Potensial Alami Hepatitis Kronis*. <https://sehatnegeriku.kemkes.go.id/baca/umum/20170726/3021882/150-ribu-orang-potensial-alami-hepatitis-kronis/>
- Kim, C. W., & Chang, K. M. (2013). Hepatitis C virus: virology and life cycle. *Clinical and molecular hepatology*, 19(1), 17–25. <https://doi.org/10.3350/cmh.2013.19.1.17>
- Kinoshita, A., Onoda, H., Fushiya, N., Koike, K., Nishino, H., & Tajiri, H. (2015). Staging systems for hepatocellular carcinoma: Current status and future perspectives. *World journal of hepatology*, 7(3), 406–424. <https://doi.org/10.4254/wjh.v7.i3.406>
- Kirstein, M. M., & Vogel, A. (2014). The pathogenesis of hepatocellular carcinoma. *Digestive diseases* (Basel, Switzerland), 32(5), 545–553. <https://doi.org/10.1159/000360499>
- Kitada, T., Seki, S., Nakatani, K., Kawada, N., Kuroki, T., & Monna, T. (1997). Hepatic expression of c-Myb in chronic human liver disease. *Hepatology* (Baltimore, Md.), 26(6), 1506–1512. <https://doi.org/10.1053/jhep.1997.v26.pm0009397991>
- Krammer, J., Digel, M., Eehalt, F., Stremmel, W., Füllekrug, J., & Eehalt, R. (2011). Overexpression of CD36 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells. *International journal of medical sciences*, 8(7), 599–614. <https://doi.org/10.7150/ijms.8.599>
- Kuang, J., Yan, X., Genders, A. J., Granata, C., & Bishop, D. J. (2018). An overview of technical considerations when using quantitative real-time PCR analysis of gene expression in human exercise research. *PloS one*, 13(5), e0196438. <https://doi.org/10.1371/journal.pone.0196438>
- Kumar, V., & Mahato, R. I. (2015). Delivery and targeting of miRNAs for treating liver fibrosis. *Pharmaceutical research*, 32(2), 341–361. <https://doi.org/10.1007/s11095-014-1497-x>
- Lan, S. H., Wu, S. Y., Zuchini, R., Lin, X. Z., Su, I. J., Tsai, T. F., Lin, Y. J., Wu, C. T., & Liu, H. S. (2014). Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. *Hepatology* (Baltimore, Md.), 59(2), 505–517. <https://doi.org/10.1002/hep.26659>

- Lee, K. S., Buck, M., Houglum, K., & Chojkier, M. (1995). Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. *The Journal of clinical investigation*, 96(5), 2461–2468. <https://doi.org/10.1172/JCI118304>
- Lestari, P., 2017. *Profil Ekspresi hsa-miR-29c-3p dan mRNA PTEN pada Karsinoma Hepatoseluler* (Thesis, Universitas Gadjah Mada)
- Li, B., Liu, J., Xin, X., Zhang, L., Zhou, J., Xia, C., Zhu, W., & Yu, H. (2021). MiR-34c promotes hepatic stellate cell activation and Liver Fibrogenesis by suppressing ACSL1 expression. *International journal of medical sciences*, 18(3), 615–625. <https://doi.org/10.7150/ijms.51589>
- Li, J., Liu, X., Li, C., & Wang, W. (2019). miR-224-5p inhibits proliferation, migration, and invasion by targeting PIK3R3/AKT3 in uveal melanoma. *Journal of cellular biochemistry*, 120(8), 12412–12421. <https://doi.org/10.1002/jcb.28507>
- Li, T., Xie, J., Shen, C., Cheng, D., Shi, Y., Wu, Z., Zhan, Q., Deng, X., Chen, H., Shen, B., Peng, C., Li, H., & Zhu, Z. (2014). miR-150-5p inhibits hepatoma cell migration and invasion by targeting MMP14. *PloS one*, 9(12), e115577. <https://doi.org/10.1371/journal.pone.0115577>
- Li, W. Q., Chen, C., Xu, M. D., Guo, J., Li, Y. M., Xia, Q. M., Liu, H. M., He, J., Yu, H. Y., & Zhu, L. (2011). The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. *The FEBS journal*, 278(9), 1522–1532. <https://doi.org/10.1111/j.1742-4658.2011.08075.x>
- Li, X. J., Ren, Z. J., & Tang, J. H. (2014). MicroRNA-34a: a potential therapeutic target in human cancer. *Cell death & disease*, 5(7), e1327. <https://doi.org/10.1038/cddis.2014.270>
- Liu, F., & Di Wang, X. (2019). miR-150-5p represses TP53 tumor suppressor gene to promote proliferation of colon adenocarcinoma. *Scientific reports*, 9(1), 6740. <https://doi.org/10.1038/s41598-019-43231-5>
- Liu, Q., Bengmark, S., & Qu, S. (2010). The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Lipids in health and disease*, 9, 42. <https://doi.org/10.1186/1476-511X-9-42>
- Liu, Y., Wu, C., Wang, Y., Wen, S., Wang, J., Chen, Z., He, Q., & Feng, D. (2014). Expression of miR-224, miR-145, and their putative target ADAM17 in hepatocellular carcinoma. *Acta biochimica et biophysica Sinica*, 46(8), 720–722. <https://doi.org/10.1093/abbs/gmu052>
- Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* (San Diego, Calif.), 25(4), 402–408. <https://doi.org/10.1006/meth.2001.1262>
- Lo, R. C., & Kim, H. (2017). Histopathological evaluation of liver fibrosis and cirrhosis regression. *Clinical and molecular hepatology*, 23(4), 302–307. <https://doi.org/10.3350/cmh.2017.0078>
- Macfarlane, L. A., & Murphy, P. R. (2010). MicroRNA: Biogenesis, Function and Role in Cancer. *Current genomics*, 11(7), 537–561. <https://doi.org/10.2174/138920210793175895>

- Mamdouh, S., Khorshed, F., Aboushousha, T., Hamdy, H., Diab, A., Seleem, M., & Saber, M. (2017). Evaluation of Mir-224, Mir-215 and Mir-143 as Serum Biomarkers for HCV Associated Hepatocellular Carcinoma. *Asian Pacific journal of cancer prevention : APJCP*, 18(11), 3167–3171. <https://doi.org/10.22034/APJCP.2017.18.11.3167>
- Mao, B., & Wang, G. (2015). MicroRNAs involved with hepatocellular carcinoma (Review). *Oncology reports*, 34(6), 2811–2820. <https://doi.org/10.3892/or.2015.4275>
- Mashek, D. G., Li, L. O., & Coleman, R. A. (2007). Long-chain acyl-CoA synthetases and fatty acid channeling. *Future lipidology*, 2(4), 465–476. <https://doi.org/10.2217/17460875.2.4.465>
- McCormick, P.A. and Jalan, R. (2018). Hepatic Cirrhosis. In J.S. Dooley, A.S.F. Lok, G. Garcia-Tsao and M. Pinzani (Ed.). *Sherlock's Diseases of the Liver and Biliary System*. <https://doi.org/10.1002/9781119237662.ch8>
- McGlynn, K. A., Petrick, J. L., & El-Serag, H. B. (2021). Epidemiology of Hepatocellular Carcinoma. *Hepatology* (Baltimore, Md.), 73 Suppl 1(Suppl 1), 4–13. <https://doi.org/10.1002/hep.31288>
- Mehinovic, L., Islamagic, E., Husic-Selimovic, A., Kurtovic-Kozaric, A., Vukobrat-Bijedic, Z., & Suljevic, D. (2018). Evaluation of Diagnostic Efficiency of Alpha-Fetoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Single-Center Experience. *Open access Macedonian journal of medical sciences*, 6(9), 1668–1673. <https://doi.org/10.3889/oamjms.2018.344>
- miRBase (2020a, January 03). *Stem-loop sequence hsa-mir-34a*. [https://www.mirbase.org/cgi-bin/mirna\\_entry.pl?acc=MI0000268](https://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000268)
- miRBase (2020b, January 04). *Stem-loop sequence hsa-mir-150*. [https://www.mirbase.org/cgi-bin/mirna\\_entry.pl?acc=MI0000479](https://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000479)
- miRBase (2020c, January 05). *Stem-loop sequence hsa-mir-224*. [https://www.mirbase.org/cgi-bin/mirna\\_entry.pl?acc=MI0000301](https://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000301)
- Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., & Caraglia, M. (2014). Mir-34: a new weapon against cancer?. *Molecular therapy. Nucleic acids*, 3(9), e194. <https://doi.org/10.1038/mtna.2014.47>
- Mjelle, R., Dima, S. O., Bacalbasa, N., Chawla, K., Sorop, A., Cucu, D., Herlea, V., Sætrom, P., & Popescu, I. (2019). Comprehensive transcriptomic analyses of tissue, serum, and serum exosomes from hepatocellular carcinoma patients. *BMC cancer*, 19(1), 1007. <https://doi.org/10.1186/s12885-019-6249-1>
- Mokdad, A. A., Lopez, A. D., Shahrzad, S., Lozano, R., Mokdad, A. H., Stanaway, J., Murray, C. J., & Naghavi, M. (2014). Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. *BMC medicine*, 12, 145. <https://doi.org/10.1186/s12916-014-0145-y>
- Mokdad, A.A., Singal, A.G., Yopp, A.C. (2015). Liver Cancer. *JAMA*, 314(24), 2701. doi:10.1001/jama.2015.15425



- Moss, M. L., & Minond, D. (2017). Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. *Mediators of inflammation*, 2017, 9673537. <https://doi.org/10.1155/2017/9673537>
- Mourad, L., El-Ahwany, E., Zoheiry, M., Abu-Taleb, H., Hassan, M., Ouf, A., Rahim, A. A., Hassanien, M., & Zada, S. (2018). Expression analysis of liver-specific circulating microRNAs in HCV-induced hepatocellular Carcinoma in Egyptian patients. *Cancer biology & therapy*, 19(5), 400–406. <https://doi.org/10.1080/15384047.2018.1423922>
- Muir, K., Hazim, A., He, Y., Peyressatre, M., Kim, D. Y., Song, X., & Beretta, L. (2013). Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. *Cancer research*, 73(15), 4722–4731. <https://doi.org/10.1158/0008-5472.CAN-12-3797>
- Muniategui, A., Pey, J., Planes, F. J., Rubio, A. (2013). Joint analysis of miRNA and mRNA expression data. *Briefings in Bioinformatics*, 14(3), 263–278. <https://doi.org/10.1093/bib/bbs028>
- Murphy, B. (2013). Chapter 254 - ADAM17, Tumor Necrosis Factor  $\alpha$ -Convertase. In N.D. Rawlings, G. Salvesen (Ed.). *Handbook of Proteolytic Enzymes* (Third Edition., pp. 1126–1130). Academic Press.
- Nakao, K., Miyaaki, H., & Ichikawa, T. (2014). Antitumor function of microRNA-122 against hepatocellular carcinoma. *Journal of gastroenterology*, 49(4), 589–593. <https://doi.org/10.1007/s00535-014-0932-4>
- Nakata, Y., Shetzline, S., Sakashita, C., Kalota, A., Rallapalli, R., Rudnick, S. I., Zhang, Y., Emerson, S. G., & Gewirtz, A. M. (2007). c-Myb contributes to G2/M cell cycle transition in human hematopoietic cells by direct regulation of cyclin B1 expression. *Molecular and cellular biology*, 27(6), 2048–2058. <https://doi.org/10.1128/MCB.01100-06>
- Naseha, A.D., Purnamaningsih, N.'A., Hardjo, K. (2021). Gambaran Pendoron Darah di UTD PMI Kabupaten Bantul Tahun 2020. *Jurnal Ilmiah Pannmed*, 16(3), 738– 43. <https://doi.org/10.36911/pannmed.v16i3.1228>
- Nault, J. C. (2014). Pathogenesis of hepatocellular carcinoma according to aetiology. Best practice & research. *Clinical gastroenterology*, 28(5), 937–947. <https://doi.org/10.1016/j.bpg.2014.08.006>
- NCBI Gene (2019). *ACSL1 acyl-CoA synthetase long chain family member 1* [Homo sapiens (human)]. <https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=2180>
- NCBI Gene (2022a, May 13). *ACSL1 acyl-CoA synthetase long chain family member 1* [Homo sapiens (human)]. <https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=2180>
- Nomair, A. M., Issa, N. M., Madkour, M. A., & Shamseya, M. M. (2020). The clinical significance of serum miRNA-224 expression in hepatocellular carcinoma. *Clinical and experimental hepatology*, 6(1), 20–27. <https://doi.org/10.5114/ceh.2020.93052>



- O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. *Frontiers in endocrinology*, 9, 402. <https://doi.org/10.3389/fendo.2018.00402>
- Okajima, W., Komatsu, S., Ichikawa, D., Miyamae, M., Kawaguchi, T., Hirajima, S., Ohashi, T., Imamura, T., Kiuchi, J., Arita, T., Konishi, H., Shiozaki, A., Moriumura, R., Ikoma, H., Okamoto, K., Taniguchi, H., Itoh, Y., & Otsuji, E. (2016). Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. *Oncotarget*, 7(33), 53820–53836. <https://doi.org/10.18632/oncotarget.10781>
- Oliviero, B., Mantovani, S., Varchetta, S., Mele, D., Grossi, G., Ludovisi, S., Nuti, E., Rossello, A., & Mondelli, M. U. (2017). Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity. *Journal of hepatology*, 66(6), 1130–1137. <https://doi.org/10.1016/j.jhep.2017.01.032>
- Paschos, P., & Paletas, K. (2009). Non alcoholic fatty liver disease and metabolic syndrome. *Hippokratia*, 13(1), 9–19
- Peng, X., Guo, C., Wu, Y., Ying, M., Chang, R., Song, L., Zhan, L., & Zhan, X. (2021). miR 224 5p regulates the proliferation, migration and invasion of pancreatic mucinous cystadenocarcinoma by targeting PTEN. *Molecular medicine reports*, 23(5), 346. <https://doi.org/10.3892/mmr.2021.11985>
- Pinter, M., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W. (2016). Cancer and liver cirrhosis: implications on prognosis and management. *ESMO open*, 1(2), e000042. <https://doi.org/10.1136/esmoopen-2016-000042>
- Pinto, R. B., Schneider, A. C., & da Silveira, T. R. (2015). Cirrhosis in children and adolescents: An overview. *World journal of hepatology*, 7(3), 392–405. <https://doi.org/10.4254/wjh.v7.i3.392>
- Pu, Q., Huang, Y., Lu, Y., Peng, Y., Zhang, J., Feng, G., Wang, C., Liu, L., & Dai, Y. (2016). Tissue-specific and plasma microRNA profiles could be promising biomarkers of histological classification and TNM stage in non-small cell lung cancer. *Thoracic cancer*, 7(3), 348–354. <https://doi.org/10.1111/1759-7714.12317>
- Qiao, D. D., Yang, J., Lei, X. F., Mi, G. L., Li, S. L., Li, K., Xu, C. Q., & Yang, H. L. (2017). Expression of microRNA-122 and microRNA-22 in HBV-related liver cancer and the correlation with clinical features. *European review for medical and pharmacological sciences*, 21(4), 742–747
- Ramadori, P., Cubero, F. J., Liedtke, C., Trautwein, C., & Nevzorova, Y. A. (2017). Alcohol and Hepatocellular Carcinoma: Adding Fuel to the Flame. *Cancers*, 9(10), 130. <https://doi.org/10.3390/cancers9100130>
- Ramakrishna, G., Rastogi, A., Trehanpati, N., Sen, B., Khosla, R., & Sarin, S. K. (2013). From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. *Liver cancer*, 2(3-4), 367–383. <https://doi.org/10.1159/000343852>

- Ratnasari, N., Nurdjanah, S., Sadewa, A. H., Hakimi, M., & Yano, Y. (2017). Difference of polymorphism VEGF-gene rs699947 in Indonesian chronic liver disease population. *PloS one*, 12(8), e0183503. <https://doi.org/10.1371/journal.pone.0183503>
- Rawla, P., Sunkara, T., Muralidharan, P., & Raj, J. P. (2018). Update in global trends and aetiology of hepatocellular carcinoma. *Contemporary oncology* (Poznan, Poland), 22(3), 141–150. <https://doi.org/10.5114/wo.2018.78941>
- Reddy K. B. (2015). MicroRNA (miRNA) in cancer. *Cancer cell international*, 15, 38. <https://doi.org/10.1186/s12935-015-0185-1>
- Rini, S. (2015). Sindrom Metabolik. *Medical Journal of Lampung University*, 4(4), 88
- Rocks, N., Paulissen, G., Quesada Calvo, F., Polette, M., Gueders, M., Munaut, C., Foidart, J. M., Noel, A., Birembaut, P., & Cataldo, D. (2006). Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). *British journal of cancer*, 94(5), 724–730. <https://doi.org/10.1038/sj.bjc.6602990>
- Romanelli, R. G., & Stasi, C. (2016). Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis. *Current drug targets*, 17(15), 1804–1817. <https://doi.org/10.2174/1389450117666160613101413>
- Roy, S., Benz, F., Luedde, T., & Roderburg, C. (2015). The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis. *Hepatobiliary surgery and nutrition*, 4(1), 24–33. <https://doi.org/10.3978/j.issn.2304-3881.2015.01.05>
- Sajja, K. C., Mohan, D. P., & Rockey, D. C. (2014). Age and ethnicity in cirrhosis. *Journal of investigative medicine : the official publication of the American Federation for Clinical Research*, 62(7), 920–926. <https://doi.org/10.1097/JIM.0000000000000106>
- Sathipati, S. Y., & Ho, S. Y. (2020). Novel miRNA signature for predicting the stage of hepatocellular carcinoma. *Scientific Reports*, 10(14452). <https://doi.org/10.1038/s41598-020-71324-z>
- Sauzay, C., Petit, A., Bourgeois, A. M., Barbare, J. C., Chauffert, B., Galmiche, A., & Houessinon, A. (2016). Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. *Clinica chimica acta; international journal of clinical chemistry*, 463, 39–44. <https://doi.org/10.1016/j.cca.2016.10.006>
- Scaglione, S., Kliethermes, S., Cao, G., Shoham, D., Durazo, R., Luke, A., & Volk, M. L. (2015). The Epidemiology of Cirrhosis in the United States: A Population-based Study. *Journal of clinical gastroenterology*, 49(8), 690–696. <https://doi.org/10.1097/MCG.0000000000000208>
- Scheel, T. K., & Rice, C. M. (2013). Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. *Nature medicine*, 19(7), 837–849. <https://doi.org/10.1038/nm.3248>
- Schlageter, M., Terracciano, L. M., D'Angelo, S., & Sorrentino, P. (2014). Histopathology of hepatocellular carcinoma. *World journal of*

- gastroenterology*, 20(43), 15955–15964.  
<https://doi.org/10.3748/wjg.v20.i43.15955>
- Schmidt-Arras, D., & Rose-John, S. (2019). Regulation of Fibrotic Processes in the Liver by ADAM Proteases. *Cells*, 8(10), 1226.  
<https://doi.org/10.3390/cells8101226>
- Schuppan, D., & Afdhal, N. H. (2008). Liver cirrhosis. *Lancet* (London, England), 371(9615), 838–851. [https://doi.org/10.1016/S0140-6736\(08\)60383-9](https://doi.org/10.1016/S0140-6736(08)60383-9)
- Sethi, G., Sung, B., & Aggarwal, B. B. (2008). Nuclear factor-kappaB activation: from bench to bedside. *Experimental biology and medicine* (Maywood, N.J.), 233(1), 21–31. <https://doi.org/10.3181/0707-MR-196>
- Shaheen, N., Zayed, N., Riad, N. M., Tamim, H. H., Shahin, R., Labib, D. A., ELsheikh, S. M., Moneim, R. A., Yosry, A., & Khalifa, R. H. (2018). Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients. *Virus research*, 255, 77–84. <https://doi.org/10.1016/j.virusres.2018.07.004>
- Sharma, S., Khalili, K., & Nguyen, G. C. (2014). Non-invasive diagnosis of advanced fibrosis and cirrhosis. *World journal of gastroenterology*, 20(45), 16820–16830.  
<https://doi.org/10.3748/wjg.v20.i45.16820>
- Shehata, R. H., Abdelmoneim, S. S., Osman, O. A., Hasanain, A. F., Osama, A., Abdelmoneim, S. S., & Toraih, E. A. (2017). Deregulation of miR-34a and Its Chaperon Hsp70 in Hepatitis C virus-Induced Liver Cirrhosis and Hepatocellular Carcinoma Patients. *Asian Pacific journal of cancer prevention : APJCP*, 18(9), 2395–2401.  
<https://doi.org/10.22034/APJCP.2017.18.9.2395>
- Shehab-Eldeen, S., Nada, A., Abou-Elela, D., El-Naidany, S., Arafat, E., & Omar, T. (2019). Diagnostic Performance of microRNA-122 and microRNA-224 in Hepatitis C Virus-Induced Hepatocellular Carcinoma (HCC). *Asian Pacific journal of cancer prevention : APJCP*, 20(8), 2515–2522. <https://doi.org/10.31557/APJCP.2019.20.8.2515>
- Simeonova, P. P., Gallucci, R. M., Hulderman, T., Wilson, R., Kommineni, C., Rao, M., & Luster, M. I. (2001). The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. *Toxicology and applied pharmacology*, 177(2), 112–120.  
<https://doi.org/10.1006/taap.2001.9304>
- Singh, A. B., Kan, C. F., Dong, B., & Liu, J. (2016). SREBP2 Activation Induces Hepatic Long-chain Acyl-CoA Synthetase 1 (ACSL1) Expression in Vivo and in Vitro through a Sterol Regulatory Element (SRE) Motif of the ACSL1 C-promoter. *The Journal of biological chemistry*, 291(10), 5373–5384. <https://doi.org/10.1074/jbc.M115.696872>
- Song, K., Han, C., Dash, S., Balart, L. A., & Wu, T. (2015). MiR-122 in hepatitis B virus and hepatitis C virus dual infection. *World journal of hepatology*, 7(3), 498–506. <https://doi.org/10.4254/wjh.v7.i3.498>
- Spaniel, C., Honda, M., Selitsky, S. R., Yamane, D., Shimakami, T., Kaneko, S., Lanford, R. E., & Lemon, S. M. (2013). microRNA-122 abundance in

- hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. *PloS one*, 8(10), e76867. <https://doi.org/10.1371/journal.pone.0076867>
- Stasi, C., Silvestri, C., Voller, F., & Cipriani, F. (2015). Epidemiology of Liver Cirrhosis. *Journal of clinical and experimental hepatology*, 5(3), 272. <https://doi.org/10.1016/j.jceh.2015.06.002>
- Suresh, D., Srinivas, A. N., & Kumar, D. P. (2020). Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. *Frontiers in oncology*, 10, 601710. <https://doi.org/10.3389/fonc.2020.601710>
- Szabo, G., & Bala, S. (2013). MicroRNAs in liver disease. *Nature reviews. Gastroenterology & hepatology*, 10(9), 542–552. <https://doi.org/10.1038/nrgastro.2013.87>
- Szabo, G., Sarnow, P., & Bala, S. (2012). MicroRNA silencing and the development of novel therapies for liver disease. *Journal of hepatology*, 57(2), 462–466. <https://doi.org/10.1016/j.jhep.2012.01.030>
- Tai, Y., Zhao, C., Gao, J., Lan, T., & Tong, H. (2021). Identification of miRNA-target gene regulatory networks in liver fibrosis based on bioinformatics analysis. *PeerJ*, 9, e11910. <https://doi.org/10.7717/peerj.11910>
- Tambunan, A., Mulyadi, Y., Kahtan, M.I. (2013). Karakteristik Pasien Sirosis Hati di RSUD Dr. Soedarso Pontianak Periode Januari 2008 Desember 2010. *Jurnal Mahasiswa Fakultas Kedokteran Untan*, 2(1)
- Tellez-Gabriel, M., Ory, B., Lamoureux, F., Heymann, M. F., & Heymann, D. (2016). Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis. *International journal of molecular sciences*, 17(12), 2142. <https://doi.org/10.3390/ijms17122142>
- Testino, G., Leone, S., & Borro, P. (2014). Alcohol and hepatocellular carcinoma: a review and a point of view. *World journal of gastroenterology*, 20(43), 15943–15954. <https://doi.org/10.3748/wjg.v20.i43.15943>
- Thakral, S., & Ghoshal, K. (2015). miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir. *Current gene therapy*, 15(2), 142–150. <https://doi.org/10.2174/1566523214666141224095610>
- Tichý, M., Knopfová, L., Jarkovský, J., Pekarčíková, L., Veverková, L., Vlček, P., Katolická, J., Čapov, I., Hermanová, M., Šmarda, J., & Beneš, P. (2016). Overexpression of c-Myb is associated with suppression of distant metastases in colorectal carcinoma. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*, 37(8), 10723–10729. <https://doi.org/10.1007/s13277-016-4956-7>
- Toosi A. E. (2015). Liver Fibrosis: Causes and Methods of Assessment, A Review. *Romanian journal of internal medicine = Revue roumaine de medecine interne*, 53(4), 304–314. <https://doi.org/10.1515/rjim-2015-0039>
- Tsai, W. C., Hsu, P. W., Lai, T. C., Chau, G. Y., Lin, C. W., Chen, C. M., Lin, C. D., Liao, Y. L., Wang, J. L., Chau, Y. P., Hsu, M. T., Hsiao, M., Huang,

- H. D., & Tsou, A. P. (2009). MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. *Hepatology* (Baltimore, Md.), 49(5), 1571–1582. <https://doi.org/10.1002/hep.22806>
- Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014). Liver cirrhosis. *Lancet* (London, England), 383(9930), 1749–1761. [https://doi.org/10.1016/S0140-6736\(14\)60121-5](https://doi.org/10.1016/S0140-6736(14)60121-5)
- Vaz, J., Eriksson, B., Strömberg, U., Buchebner, D., & Midlöv, P. (2020). Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study. *BMC gastroenterology*, 20(1), 84. <https://doi.org/10.1186/s12876-020-01239-6>
- Wacker, M. J., & Godard, M. P. (2005). Analysis of one-step and two-step real-time RT-PCR using SuperScript III. *Journal of biomolecular techniques : JBT*, 16(3), 266–271
- Wang, F. Z., Sha, L., Zhang, W. Y., Wu, L. Y., Qiao, L., Li, N., Zhang, X. D., & Ye, L. H. (2007). Involvement of hepatitis B X-interacting protein (HBXIP) in proliferation regulation of cells. *Acta pharmacologica Sinica*, 28(3), 431–438. <https://doi.org/10.1111/j.1745-7254.2007.00531.x>
- Wang, F., Ren, X., & Zhang, X. (2015). Role of microRNA-150 in solid tumors. *Oncology letters*, 10(1), 11–16. <https://doi.org/10.3892/ol.2015.3170>
- Wang, H., Peng, R., Wang, J., Qin, Z., & Xue, L. (2018). Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. *Clinical epigenetics*, 10, 59. <https://doi.org/10.1186/s13148-018-0492-1>
- Wang, K., Yuan, Y., Cho, J. H., McClarty, S., Baxter, D., & Galas, D. J. (2012). Comparing the MicroRNA spectrum between serum and plasma. *PloS one*, 7(7), e41561. <https://doi.org/10.1371/journal.pone.0041561>
- Wang, Y., & Lee, C. G. (2011). Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention?. *Epigenomics*, 3(2), 235–243. <https://doi.org/10.2217/epi.11.5>
- Wang, Y., Cai, X., Zhang, S., Cui, M., Liu, F., Sun, B., Zhang, W., Zhang, X., & Ye, L. (2017). HBXIP up-regulates ACSL1 through activating transcriptional factor Sp1 in breast cancer. *Biochemical and biophysical research communications*, 484(3), 565–571. <https://doi.org/10.1016/j.bbrc.2017.01.126>
- Wang, X., Zhao, Y., Lu, Q., Fei, X., Lu, C., Li, C., & Chen, H. (2020). MiR-34a-5p Inhibits Proliferation, Migration, Invasion and Epithelial-mesenchymal Transition in Esophageal Squamous Cell Carcinoma by Targeting LEF1 and Inactivation of the Hippo-YAP1/TAZ Signaling Pathway. *Journal of Cancer*, 11(10), 3072–3081. <https://doi.org/10.7150/jca.39861>
- Wei, W., Tang, H., & Tang, L. (2018). MicroRNA-34a inhibits metastasis in liver cancer cells. *Oncology letters*, 16(6), 6960–6965. <https://doi.org/10.3892/ol.2018.9555>



- Wei, X. Y., Ding, J., Tian, W. G., & Yu, Y. C. (2020). MicroRNA-122 as a diagnostic biomarker for hepatocellular carcinoma related to hepatitis C virus: a meta-analysis and systematic review. *The Journal of international medical research*, 48(8), 300060520941634. <https://doi.org/10.1177/0300060520941634>
- Wen, D. Y., Huang, J. C., Wang, J. Y., Pan, W. Y., Zeng, J. H., Pang, Y. Y., & Yang, H. (2018). Potential clinical value and putative biological function of miR-122-5p in hepatocellular carcinoma: A comprehensive study using microarray and RNA sequencing data. *Oncology letters*, 16(6), 6918–6929. <https://doi.org/10.3892/ol.2018.9523>
- Wong, M., Huang, J., George, J., Huang, J., Leung, C., Eslam, M., Chan, H., & Ng, S. C. (2019). The changing epidemiology of liver diseases in the Asia-Pacific region. *Nature reviews. Gastroenterology & hepatology*, 16(1), 57–73. <https://doi.org/10.1038/s41575-018-0055-0>
- Xiang, Y., Liu, L., Wang, Y., Li, B., Peng, J., & Feng, D. (2020). ADAM17 promotes the invasion of hepatocellular carcinoma via upregulation MMP21. *Cancer cell international*, 20, 516. <https://doi.org/10.1186/s12935-020-01556-6>
- Xu, J., Wu, C., Che, X., Wang, L., Yu, D., Zhang, T., Huang, L., Li, H., Tan, W., Wang, C., & Lin, D. (2011). Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. *Molecular carcinogenesis*, 50(2), 136–142. <https://doi.org/10.1002/mc.20712>
- Xu, Z., Liu, G., Zhang, M., Zhang, Z., Jia, Y., Peng, L., Zhu, Y., Hu, J., Huang, R., & Sun, X. (2018). miR-122-5p Inhibits the Proliferation, Invasion and Growth of Bile Duct Carcinoma Cells by Targeting ALDOA. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*, 48(6), 2596–2606. <https://doi.org/10.1159/000492702>
- Yan, G., Li, B., Xin, X., Xu, M., Ji, G., & Yu, H. (2015). MicroRNA-34a Promotes Hepatic Stellate Cell Activation via Targeting ACSL1. *Medical science monitor : international medical journal of experimental and clinical research*, 21, 3008–3015. <https://doi.org/10.12659/MSM.894000>
- Yang, G., Zhang, M., Zhao, Y., Pan, Y., Kan, M., Li, J., He, K., & Zhang, X. (2020). HNF-4 $\alpha$  inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway. *PloS one*, 15(3), e0230450. <https://doi.org/10.1371/journal.pone.0230450>
- Yano, Y., Utsumi, T., Lusida, M. I., & Hayashi, Y. (2015). Hepatitis B virus infection in Indonesia. *World journal of gastroenterology*, 21(38), 10714–10720. <https://doi.org/10.3748/wjg.v21.i38.10714>
- Yao, L., Li, F. J., Tang, Z. Q., Gao, S., & Wu, Q. Q. (2012). Smad4 expression in hepatocellular carcinoma differs by hepatitis status. *Asian Pacific journal of cancer prevention : APJCP*, 13(4), 1297–1303. <https://doi.org/10.7314/apjcp.2012.13.4.1297>
- Yu, F., Lu, Z., Chen, B., Dong, P., Zheng, J. (2015). microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular

- carcinoma. *Diagnostic Pathology* 10, 129 (2015).  
<https://doi.org/10.1186/s13000-015-0369-y>
- Zedan, A. H., Hansen, T. F., Assenholt, J., Pleckaitis, M., Madsen, J. S., & Osther, P. (2018). microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*, 40(5), 1010428318775864.  
<https://doi.org/10.1177/1010428318775864>
- Zhang, D. Y., & Friedman, S. L. (2012). Fibrosis-dependent mechanisms of hepatocarcinogenesis. *Hepatology* (Baltimore, Md.), 56(2), 769–775.  
<https://doi.org/10.1002/hep.25670>
- Zhao, M., Mishra, L., & Deng, C. X. (2018). The role of TGF- $\beta$ /SMAD4 signaling in cancer. *International journal of biological sciences*, 14(2), 111–123. <https://doi.org/10.7150/ijbs.23230>
- Zhao, X. F., Li, N., Lin, D. D., & Sun, L. B. (2020). Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis. *BioMed research international*, 2020, 5353695.  
<https://doi.org/10.1155/2020/5353695>
- Zhou, J., Zhou, W., Kong, F., Xiao, X., Kuang, H., & Zhu, Y. (2017). microRNA-34a overexpression inhibits cell migration and invasion via regulating SIRT1 in hepatocellular carcinoma. *Oncology letters*, 14(6), 6950–6954.  
<https://doi.org/10.3892/ol.2017.7090>
- Zhou, W. C., Zhang, Q. B., & Qiao, L. (2014). Pathogenesis of liver cirrhosis. *World journal of gastroenterology*, 20(23), 7312–7324.  
<https://doi.org/10.3748/wjg.v20.i23.7312>
- Zhu, R. X., Seto, W. K., Lai, C. L., & Yuen, M. F. (2016). Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. *Gut and liver*, 10(3), 332–339. <https://doi.org/10.5009/gnl15257>
- Zhu, Z., Zhang, X., Wang, G., & Zheng, H. (2014). Role of MicroRNAs in Hepatocellular Carcinoma. *Hepatitis monthly*, 14(8), e18672.  
<https://doi.org/10.5812/hepatmon.18672>